We look at how soaring food and fuel prices are affecting the tiny island nation in the western Pacific Ocean.Like much of the world, the Covid-19 pandemic and the war in Ukraine have led to supply chain issues, and rising costs.And with limited opportunities, young people are facing the question, should they stay or leave and chase careers elsewhere?Produced and presented by Frey Lindsay(Image: People gathered under the Japan-Palau Friendship bridge in Koror, Palau. Credit: Frey Lindsay/BBC)
Folgen von Business Daily
2000 Folgen
-
Folge vom 10.06.2024Economic life in Palau
-
Folge vom 09.06.2024The fight over Palau's oceansWe travel to the tiny pacific nation which wants to shrink its marine sanctuary, and open it up once more to commercial fishing.The President says it’s costing too much in lost revenue, when Palauans are already struggling.But opponents say this goes against Palau's conservationist ethos.So today we're asking - can conservation and commerce, co-exist?Produced and presented by Frey Lindsay(Image: The National Geographic Pristine Seas research vessel the Argo, in the Pacific Ocean East of Palau. Credit: Frey Lindsay)
-
Folge vom 06.06.2024The weight-loss drug revolutionDiabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.Presented by Leanna Byrne and produced by Lexy O'Connor(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)
-
Folge vom 05.06.2024Denmark and the Novo Nordisk effectIn the first of a two-part series, in collaboration with The Food Chain, we look at the impact of the success of weight-loss drug manufacturer Novo Nordisk on the small country of Denmark. The Scandinavian nation is where the company is based, and with a population of less than six million people, Novo is having an outsized impact on the economy there. Denmark is now publishing separate economic statistics, minus the pharmaceutical industry. One town in particular, Kalundborg, has seen huge change since the company set up its manufacturing facility there. We look at the impact on local business; hearing from the town's residents, who now have quite different economic prospects.Presented/producer: Adrienne Murray(Photo: The headquarters of Novo Nordisk in Denmark, viewed from above. Credit: Getty Images)